MedTrace Logo

A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome

NCT07569081 · Status: NOT_YET_RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 136

Last updated 2026-06-01

No results posted yet for this study

Summary

This study will assess the efficacy and safety of momelotinib in participants with a diagnosis of VEXAS.

Conditions

  • VEXAS Syndrome

Interventions

DRUG

Momelotinib

Momelotinib will be administered

DRUG

Glucocorticoids

Glucocorticoids (prednisone or prednisolone) will be administered

DRUG

Placebo

Placebo will be administered

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-05
Primary Completion
2028-12-06
Completion
2031-06-04
FDA Drug
Yes

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07569081 on ClinicalTrials.gov